Morgan Stanley lifts stake as Eckert & Ziegler stock gains 1.55 percent

Published on 10/09/2026 at 14:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Morgan Stanley held 5.76 percent on September 18, 2026, from 5.32 percent. Eckert & Ziegler stock costs EUR 12.41 on October 9, 2026 after EUR 12.22.

Key points in brief

Morgan Stanley reported total positions of 5.76 percent in Eckert & Ziegler on September 18, 2026, up from 5.32 percent.
Eckert & Ziegler stock was at EUR 12.41 at Lang & Schwarz on October 9, 2026, plus 1.55 percent versus EUR 12.22.
First-half 2026 revenue reached EUR 149.3 million, while adjusted EBIT fell 6.00 percent to EUR 33.30 million.
The next reported results are scheduled for November 12, 2026.

Flatlay mit Aktienzertifikat ISIN DE0005659700, Isotopenfläschchen und Dosimeter auf Marmor — Eckert & Ziegler DE0005659700 Medizintechnik: Flatlay mit Aktienzertifikat, Isotopenfläschchen, Dosimeter und Elementen-Karten, Illustration mit AI erstellt.

Eckert & Ziegler (ISIN DE0005659700) stock was trading at EUR 12.41 at Lang & Schwarz on October 9, 2026 at 2:37 p.m. CEST, up 1.55 percent versus EUR 12.22. finanzen.net reported on September 24, 2026 that Morgan Stanley's total position had reached 5.76 percent on September 18, up from 5.32 percent.

Three dated signals for the stock

On July 22, 2026, a BaFin review examined the accounting treatment of the Pentixapharm spin-off in Eckert & Ziegler's 2024 consolidated accounts. On August 13, 2026, the company reported first-half revenue of EUR 149.3 million and adjusted EBIT of EUR 33.30 million, down 6.00 percent from EUR 35.40 million in the prior-year period, according to Trading-Treff. The September 24 voting-rights notice is the latest of these three dated signals.

What does the 5.76 percent stake mean?

The Morgan Stanley disclosure gives the market a concrete ownership figure, but it does not itself establish a change in operating guidance. Eckert & Ziegler had retained its 2026 targets of EUR 320 million in revenue and EUR 80 million in adjusted EBIT after the first half, according to Trading-Treff. The contrast is material: first-half revenue was EUR 149.3 million, while adjusted EBIT was EUR 33.30 million.

Next reporting date

The next reported results are scheduled for November 12, 2026, according to the company calendar cited by Makkler. Eckert & Ziegler develops isotope technology for medical, scientific and measurement applications, with Medical and Isotope Products as its two operating segments, according to its investor-relations page.

Stock remains below its yearly high

The Lang & Schwarz quote stood 29.95 percent below the EUR 17.73 52-week high and EUR 0.50 above the EUR 11.91 low on October 9, 2026. The primary listing is Xetra, where the stock trades in euros.

The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.